Rhythm Q2 Revenue Jumps 19% to $71.3M on Acquired HO Launch; Cash Runway Extended
RYTM sits 42% above its 52-week low of $74.5 on elevated volume (2.0× avg).
Summary
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3 million, a 19% sequential increase fueled by the U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company disclosed multiple executive 10b5-1 trading plans and a severance agreement for its CHRO.
Key Events · Earnings and Guidance · RYTM
-
Q2 Revenue Hits $71.3M
Net product revenue grew 19% sequentially to $71.3 million, driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity. U.S. revenue alone jumped 38% quarter-over-quarter to $51.0 million.
-
Strong Launch Metrics
Over 400 patient start forms were received from approximately 300 prescribers since the March 2026 FDA approval, indicating robust early demand for the new indication.
-
Cash Runway Extended
Cash and short-term investments totaled $330.9 million as of June 30, 2026, which management expects to fund operations for at least 24 months.
-
Executive 10b5-1 Trading Plans
CEO David Meeker adopted a plan to sell up to 300,000 shares; CFO Hunter Smith, EVP Yann Mazzabraud, CSO Alastair Garfield, and EVP Jennifer Lee also adopted plans. Director Lynn Tetrault terminated a prior plan.
Analysis · RYTM · Life Sciences
Rhythm's Q2 2026 results show a sharp revenue acceleration driven by the recent U.S. launch of IMCIVREE for acquired hypothalamic obesity. Product revenue of $71.3 million grew 19% sequentially, with U.S. sales surging 38% quarter-over-quarter. The company received over 400 patient start forms from ~300 prescribers since the March 2026 FDA approval, signaling strong early demand. Operating loss widened to $48.6 million as SG&A spending ramped to support the launch, but the $330.9 million cash position is sufficient for at least 24 months. The filing also discloses multiple executive 10b5-1 trading plans, including the CEO's plan to sell up to 300,000 shares, and a severance agreement for the Chief Human Resources Officer. These insider sales plans, while pre-arranged, add a layer of caution alongside the strong commercial momentum.
At the time of this filing, RYTM was trading at $105.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.